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Purpose: Bietti crystalline dystrophy (BCD) is a rare autosomal recessive disorder caused by mutation of the cytochrome
P450, family 4, subfamily V, polypeptide 2 (CYP4V2) gene and characterized by retinal pigmentary abnormalities and
scattered deposits of crystals in the retina and the marginal cornea. The aim of this study was to investigate the spectrum
of mutations in CYP4V2 in Lebanese families, and to characterize the phenotype of patients affected with BCD.
Methods: Nine patients from three unrelated Lebanese families were clinically and molecularly investigated. Detailed
characterization of the patients’ phenotype was performed with comprehensive ophthalmic examination, color vision
study,  fundus  photography,  visual  field  testing,  retinal  fluorescein  angiography,  electroretinography,  and
electrooculography. One family was followed for 12 years. The 11 exons of the CYP4V2 gene were sequenced.
Results: Symptoms consisting of night blindness, loss of paracentral visual field, and disturbed color vision were apparent
during the third decade of life. Ophthalmoscopy revealed posterior pole crystalline deposits and areas of retinal pigment
epithelium  atrophy.  Fluorescein  angiography  disclosed  geographic  areas  of  the  pigment  epithelium  layer  and
choriocapillaris atrophy in the posterior pole and fundus periphery. The most striking findings were those of normal
electroretinographic responses in some patients and clinical heterogeneity. Two mutations in CYP4V2 were found: p.I111T
(c.332T>C) in exon 3 in two families and the novel p.V458M (c.1372G>A) mutation in exon 9 in one family.
Conclusions: These patients are affected with Bietti crystalline dystrophy without corneal involvement. Variation in
disease severity and electroretinographic responses suggests that environmental or additional genetic factors influence the
course of the retinal disease. The CYP4V2 p.I111T (c.332T>C) mutant allele may be especially prevalent among patients
with BCD in Lebanon, resulting from a single founder.
Bietti crystalline corneoretinal dystrophy (BCD; OMIM
210370) is a retinal degeneration first described by Bietti in
1937  [1,2].  BCD  is  characterized  by  multiple  glistening
intraretinal crystals scattered over the fundus, a degeneration
of the retina, and sclerosis of the choroidal vessels, ultimately
resulting in progressive night blindness and constriction of the
visual field. Two types of BCD have been described: one with
corneal  crystalline  deposits  (one  quarter  to  one  third  of
patients  with  BCD)  and  a  second  type  with  no  corneal
involvement and no limbal crystalline deposits, called Bietti
crystalline fundus dystrophy (BCD) or crystalline retinopathy
[1].  The  mode  of  inheritance  is  autosomal  recessive,  and
mutations of the cytochrome P450, family 4, subfamily V,
polypeptide 2 (CYP4V2) gene, a novel family member of the
cytochrome P450 genes widely expressed in the human heart,
brain, placenta, lung, liver, and most abundantly in the retina
and the retinal pigment epithelium, have been reported [1-9].
BCD is a global disease that appears to be more common
in individuals of Asian descent [5,10]. In the Middle East, a
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few  cases  have  been  reported  [11]  but  none  molecularly
investigated.
The purpose of this paper is to report for the first time on
the clinical and molecular analysis in three Lebanese families
with BCD, discuss the genotype-phenotype correlations as
well as expose a 12-year follow-up in one family in which a
novel mutation was identified.
METHODS
This study was granted approval by the Hotel-Dieu de France
of Beirut Committee on Clinical Investigation and conformed
to the tenets of the Declaration of Helsinki.
Clinical investigations: Otherwise good health except
eye findings, one Maronite and 2 Shiite unrelated Lebanese
families  with  clinical  criteria  of  BCD  syndrome  were
investigated  (Figure  1).  Nine  affected  individuals  were
examined extensively, including a comprehensive ophthalmic
examination, color vision study, fundus photos, automated
and Goldmann perimetry, routine blood tests, and molecular
analysis.
Molecular studies: After informed consent was obtained
from all the families, EDTA blood samples were collected,
and DNA extracted on the spot for genetic studies. Eleven
DNA samples were collected for this study from members of
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1182the three families (Figure 1): nine affected individuals and two
parents  (family  1:I-1  and  I-2).  DNA  was  extracted  from
lymphocytes with standard salt-precipitation method.
Polymerase chain reaction amplification: The CYP4V2
gene is made up of 11 exons. Intronic primers were designed
using the Primer 3 software (Table 1). DNA sequences were
obtained from the Human Genome Browser (UCSC database
access number NM_207352) by comparing genomic DNA
with cDNA sequences.
Fluorescent sequencing: All PCR-amplified fragments
of the 11 exons of CYP4V2 gene were fluorescently sequenced
using  an  ABI  3130  automated  sequencer  (Applied
Biosystems,  Foster  City,  CA).  Electropherograms  were
compared  to  reference  sequences  using  the  Sequencher
software v4.2 (Gene Codes Corporation, Ann Arbor, MI) and
ChromasPro v1.5 (Technelysium, Tewantin, Australia).
Polymerase chain reaction-restriction fragment length
polymorphism: Fifteen µl of the amplified product including
a novel identified variant were digested with 7.5 units of the
NlaIII  restriction  enzyme  (New  England  Biolabs  Inc.,
Ipswich, MA) overnight and electrophoresed on 2% agarose.
RESULTS
Clinical findings: Fifteen patients were examined in total.
Nine  patients  were  affected,  and  the  remaining  six
asymptomatic  individuals  were  examined  in  the  genetic
counseling  setting.  The  clinical  findings  from  the  nine
affected  patients  are  summarized  in  Table  2.  Eight  were
female. Two were asymptomatic, three had visual complaints
related to nyctalopia, and four complained of decreased visual
acuity (VA). Three of the patients had blindness, while in the
others, visual acuity was preserved even in severe cases since
the central vision had remained normal at first particularly for
near,  before  decreasing  gradually.  Best-corrected  visual
acuity  (BCVA)  in  these  individuals  ranged  from  light
perception  to  Snellen  20/20.  Color  vision  testing  using
Figure  1.  Pedigrees  of  the  three
Lebanese families with Bietti crystalline
dystrophy.  Affected  individuals  are
indicated by filled symbols. DNA was
available for all members of family 1,
for individuals II-3 and II-5 of family 2,
and for individuals IV-7, V-2, V-3, and
V-9 of family 3.
TABLE 1. PCR PRIMERS FOR THE 11 EXONS OF THE CYP4V2 GENE.
Primers Forward Reverse
Exon 1 TTTTCCGGTCTTTCGCTTC AAATGCTCACTTTGGGATGG
Exon 2 CAGGCAGTTCACACATGCTC TGGAAAGCATTAAATTGCACC
Exon 3 AATTACAGGAAGGTTGTTTGATG TTCTTGAAATAACAAGTTGCACG
Exon 4 CGTTTTGGATGTTACTTTTCTCTTTC TTCCTGTTTGGGCCATTTTC
Exon 5 ACGTCTTTAGTGTCTGCCGC GATACAACGCAGAAATTGTTAGC
Exon 6 GACAATCATCGTCATTCCCAC CATCGTGAATGCACTTAATACC
Exon 7 TCACAAGAGCCTATGTTGTCG AAGAAGTTGAGCTGGTACTTAATCAG
Exon 8 TCACTCCTAATCATCGCAGC GCCTTCCTGCTCATTACACTG
Exon 9–10 CACCTGTTCTTTTTAGATGTCTGC TGTGAGAAACCCACCATCAA
Exon 11 TTCTCCTTCCACCTACTGCG TTAGGTCTAGGGGATTCAAGC
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1184Ishihara plates ranged between normal and severe color vision
deficiency. Automated visual fields when performed gave
results  ranging  between  paracentral  scotoma  and  severe
uniform alteration. The slit lamp exam did not show any
corneal  deposits,  and  the  anterior  segments  were  within
normal limits in all examined patients. Fundus photos showed
chorioretinal atrophy in all affected patients and crystalline
deposits  in  some  cases  (Figure  2).  When  performed,
electroretinography (ERG) remained within normal limits,
and electrooculography (EOG) showed an additional decrease
in the Arden ratio that was either moderately or severely
affected.
Two patients from family 1 (Figure 1) were followed up
for 12 years. Patient 1:II-1 initially had a BCVA of 20/40 OD
and  20/25  OS  in  1991.  BCVA  remained  stable  for
approximately five years and began to drop progressively to
reach 20/50 OU in 1999. The last follow-up examination at
year 12 in 2003 showed a dramatic decrease in BCVA that
became 20/120 OU with subtle changes in ocular fundoscopy
where  more  chorioretinal  atrophy  and  fewer  crystalline
deposits  were  noted.  The  cornea  and  anterior  chamber
remained  normal  during  the  entire  follow-up,  but  small
equatorial lens opacities were found in both eyes at year 1997
and remained stable afterwards. ERG was performed in 1996;
results  were  within  normal  limits  except  for  a  slightly
diminished  maximal  response  whereas  the  EOG  results
showed a decrease in the Arden ratio. Patient 1:II-2 had an
initial BCVA of 20/25 OU in 1991. BCVA OD remained
stable  during  the  first  seven  years  and  then  dramatically
dropped to 20/120 at the end of 1999 when the ocular fundus
began to show more macular chorioretinal atrophy with fewer
crystalline deposits. BCVA OS remained stable during the
entire follow-up period reaching 20/30 in 2003. Small blue
equatorial lens opacities were found in both eyes in 1999 and
remained unchanged afterwards. ERG findings in 1996 were
strictly normal, but the EOG showed a decrease in the Arden
ratio that was more important in the left eye.
Molecular  analysis:  The  exploration  of  the  entire  coding
sequence of CYP4V2 in our series allowed identification of
the causative mutation in the three families. In family 1, a
novel homozygous variation, p.V458M (c.1372G>A), was
found  in  exon  9  in  the  affected  individuals,  and  at  the
heterozygous state in their non-affected parents (Figure 3).
This mutation was confirmed with polymerase chain reaction-
restriction  fragment  length  polymorphism.  The  550  bp
amplified  product  was  digested  by  NlaIII  producing  two
fragments of 495 and 93 bp in the affected patients with an
undigested  product  of  545  bp  in  the  heterozygous  non-
affected individuals.
In families 2 and 3, a missense mutation p.I111T (c.
332T>C) was found in exon 3 at the homozygous state in the
affected individuals (Figure 4). Random DNA samples from
400  Lebanese  chromosomes  were  subsequently  tested  for
these  mutations  with  fluorescent  sequencing,  and  the
variations were absent in all chromosomes.
DISCUSSION
Here, we report three Lebanese families with Bietti crystalline
fundus  dystrophy  (BCD)  or  crystalline  retinopathy.  BCD
affects both sexes, and the onset of features usually occurs
Figure 2. Numerous retinal crystals and
chorioretinal atrophy are visible on the
fundus photos of the patients with Bietti
crystalline corneoretinal dystrophy.
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1185during the third decade of life, as was the case with our
patients. Night blindness and symptoms related to loss of the
peripheral visual field are prominent. Color vision may also
be  disturbed.  Even  in  the  asymptomatic  stage,  retinal
crystalline deposits were already readily visible [12]. BCD has
been described as a progressive disease, with a variable rate
of progression as illustrated in the present families.
Functional  tests  can  vary  widely  in  the  presence  of
identical morphologic changes in the fundus. In our cases,
fluorescein angiography (FA) performed in the two sisters
from the first family confirmed the diagnosis by revealing
geographic  areas  of  the  retinal  pigment  epithelium  and
choriocapillaris atrophy involving the macular, perimacular,
and peripapillary regions in both eyes (Figure 2). ERG within
the normal range, such as in the two affected sisters in F1, has
rarely been reported [13]. The most striking findings were
those of the first family with two sisters having decreased
visual acuity and progressive disease while maintaining a
normal  ERG.  Usually,  ERG  is  borderline  to  moderately
abnormal in the localized form, and severely abnormal in the
diffuse form. Abnormalities involve the photopic and scotopic
systems. Researchers have suggested that cones might be less
involved than rods in BCD, and that progression of BCD is
consistent with a rod-cone dystrophy pattern [14].
Figure 3. Electropherogram of the identified mutation: c.1372G>A in the CYP4V2 gene. “Patient Seq” represents the affected individual
sequence, homozygous for the mutation compared to the reference sequence “Ref Seq.”
Figure 4. Electropherogram of the identified mutation: c.332T>C in the CYP4V2 gene. “Patient Seq” represents the affected individual
sequence, homozygous for the mutation compared to the reference sequence “Ref Seq.”
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1186The analysis of the CYP4V2 gene showed an abnormality
in the three families. In family 1, a novel mutation was found:
p.V458M  (c.1372G>A).  This  variation  was  predicted  as
damaging to the protein function according to SIFT (Sorting
Intolerant  From  Tolerant)  software.  A  12-year  follow-up
showed a mild exaggeration of symptoms, with progressive
and  moderate  visual  acuity  reduction  with  the  surprising
findings of normal ERGs. This suggests the existence of less
severe  forms  of  BCD  related  to  relatively  mild  CYP4V2
mutations. In families 2 and 3, a previously reported mutation
was found, the p.I111T (c.332T>C) [10]. Both families denied
any relation with each other. However, as the families share
the same haplotype (Figure 5), we can postulate that this
mutation  derived  from  an  ancestral  mutation  that  was
geographically restricted. Clinical comparison of the families
did not show any phenotype-genotype correlation. Indeed, at
the age of 39 and 37, patients V-2 and V-4 of family 3,
respectively, presented a severe clinical phenotype; whereas
patients II-3 and II-5 of family 2 aged 34 and 30, respectively,
presented  a  less  severe  disease  suggesting  the  possible
involvement of genetic, epigenetic, or even environmental
factors in the pathogenesis of BCD. In terms of environmental
factors, lipid metabolism, and therefore diet, may play a role
in the disease. Indeed, researchers have shown that CYP4V2
may play a role in fatty acid and steroid metabolism, which
might be consistent with biochemical studies of patients with
BCD [6,15]. Abnormal choroidal fibroblast inclusions are
similar to those found in circulating lymphocytes, keratocytes,
and  conjunctival  and  skin  fibroblasts  [3].  Cultured
lymphocytes from patients with BCD lack two fatty acid-
binding proteins of 32 and 45 kDa, in comparison to age-
matched controls [16].
In conclusion, this study further confirms the role of
CYP4V2  in  the  pathogenesis  of  BCD.  We  report  a  new
mutation that is associated with a better prognosis and normal
ERG. Longitudinal studies on patients with BCD may reveal
further differences in the clinical phenotype and severity of
the disease according to their genotype.
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